Larimar Therapeutics, Inc. (Nasdaq: LRMR) announced it will host an investor webcast on June 29, 2026, at 7:45 a.m. ET to discuss updates on its nomlabofusp clinical development program for Friedreich's ataxia.

The event is expected to include a regulatory update and data from the company's ongoing long-term open-label study of nomlabofusp, which is being developed as a potential treatment for adults and children with Friedreich's ataxia.

An archived recording of the webcast will be made available on the company's website following the live event.